Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Ionis Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 28th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Ionis Pharmaceuticals Inc, consider:
89% of the company's capital comes from equity, which is greater than 74.27% of stocks in our cash flow based forecasting set.
Ionis Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 18 -- greater than 71.53% of US stocks with positive free cash flow.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 49.09% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See HSIC, PCRX, CDNA, ENTA, and HAPP.
CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that Frank Bennett, Ph.D., Ionis' executive vice president and chief scientific officer, has been awarded the 2020 Lifetime Achievement Award by…
BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and…
This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS). Under the terms of the proposed transaction, shareholders of Akcea will receive only $18.15 in cash for each share of Akcea that they own. KSF is seeking to determine whether this consideration and the process that led t